Slow Capital Inc. Has $5.55 Million Stock Position in BioNTech SE (NASDAQ:BNTX)

Slow Capital Inc. trimmed its holdings in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 5.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 48,727 shares of the company's stock after selling 2,953 shares during the quarter. BioNTech accounts for approximately 0.8% of Slow Capital Inc.'s portfolio, making the stock its 28th biggest position. Slow Capital Inc.'s holdings in BioNTech were worth $5,552,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Baillie Gifford & Co. increased its holdings in shares of BioNTech by 0.4% in the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company's stock valued at $986,750,000 after purchasing an additional 31,773 shares during the period. FMR LLC increased its position in shares of BioNTech by 797.8% in the third quarter. FMR LLC now owns 6,299,929 shares of the company's stock valued at $748,243,000 after buying an additional 5,598,190 shares in the last quarter. Fred Alger Management LLC acquired a new stake in shares of BioNTech during the third quarter valued at $59,485,000. DekaBank Deutsche Girozentrale boosted its stake in shares of BioNTech by 12.6% during the third quarter. DekaBank Deutsche Girozentrale now owns 481,397 shares of the company's stock valued at $56,886,000 after acquiring an additional 53,800 shares during the last quarter. Finally, Braidwell LP acquired a new stake in BioNTech in the 3rd quarter worth about $29,425,000. 15.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have issued reports on BNTX shares. Wells Fargo & Company started coverage on BioNTech in a research note on Wednesday, December 11th. They issued an "overweight" rating and a $170.00 price target on the stock. The Goldman Sachs Group raised BioNTech from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $90.00 to $137.00 in a research note on Friday, November 8th. Truist Financial started coverage on BioNTech in a research note on Friday, January 10th. They issued a "buy" rating and a $172.00 price objective on the stock. Berenberg Bank started coverage on BioNTech in a research note on Tuesday, November 19th. They issued a "buy" rating and a $130.00 price objective on the stock. Finally, Evercore ISI raised BioNTech from an "in-line" rating to an "outperform" rating and lifted their price objective for the company from $110.00 to $125.00 in a research note on Tuesday, November 19th. Three analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, BioNTech presently has an average rating of "Moderate Buy" and an average price target of $142.72.

BioNTech Stock Performance

Shares of NASDAQ BNTX traded up $4.55 during trading on Tuesday, reaching $124.30. The stock had a trading volume of 923,732 shares, compared to its average volume of 754,370. BioNTech SE has a one year low of $76.53 and a one year high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The stock has a market cap of $29.80 billion, a PE ratio of -59.19 and a beta of 0.18. The firm's 50 day moving average price is $116.50 and its two-hundred day moving average price is $106.57.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. During the same quarter in the previous year, the firm posted $0.73 EPS. The business's revenue for the quarter was up 38.9% compared to the same quarter last year. On average, research analysts forecast that BioNTech SE will post -3.77 earnings per share for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.